AVOSTERIDE CAP by Dr Precision is a potent therapeutic capsule containing Dutasteride, a dual 5-alpha-reductase inhibitor, designed specifically for the effective management of benign prostatic hyperplasia (BPH) in men. This medication targets the underlying hormonal cause of prostate enlargement by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), thereby reducing prostate size and significantly relieving urinary symptoms such as increased frequency, urgency, weak urine flow, and incomplete bladder emptying. Manufactured under stringent GMP and precision formulation standards by Dr Precision, AVOSTERIDE offers high bioavailability and consistent therapeutic outcomes, making it ideal for long-term therapy in aging male patients with moderate to severe BPH. Clinical evidence supports its superior efficacy compared to single-isoform inhibitors, providing up to 25% prostate volume reduction within six months and enhanced urinary function usually observed within three to six months of initiation. The capsule is also compatible for use alongside alpha-blockers to further improve symptomatic relief. Its formulation ensures stability, safety, and patient compliance essential for chronic administration in professional healthcare and pharmaceutical distribution channels.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Dutasteride |
| Mechanism of Action | Dual 5-alpha-reductase inhibition (Type I and II) |
| Therapeutic Use | Treatment of Benign Prostatic Hyperplasia (BPH) |
| Indications | Reduces prostate size, improves urinary symptoms |
| Efficacy | Approx. 25% reduction in prostate volume after 6 months |
| Onset of Action | Symptom improvement within 3 to 6 months |
| Formulation | Capsule with high bioavailability |
| Manufacturing Standards | GMP-compliant, precision formulation by Dr Precision |
| Combination Therapy | Compatible with alpha-blockers for enhanced effect |
| Marketed By | Dr Precision |
| Attributes | Description |
|---|---|
| Dosage Form | Capsule |
| Strength | Usually 0.5 mg Dutasteride (subject to packaging, please verify) |
| Active Pharmaceutical Ingredient (API) | Dutasteride |
| Pharmacological Class | 5-alpha-reductase inhibitor |
| Indication | Benign prostatic hyperplasia (BPH) |
| Packaging | Blister pack or bottle, depending on order specifications |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Shelf Life | Typically 2 years from manufacturing date |
| Administration Route | Oral |
| Regulatory Compliance | Manufactured under GMP-certified facility |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
AVOSTERIDE contains Dutasteride, which inhibits both type I and II isoforms of 5-alpha-reductase, whereas Finasteride only inhibits type II. This dual inhibition results in a more profound reduction of DHT levels and greater prostate volume shrinkage, offering superior efficacy in managing BPH symptoms.
Patients typically experience improvement in urinary symptoms such as flow and frequency within 3 to 6 months of continuous AVOSTERIDE treatment, with prostate volume reduction becoming significant by approximately 6 months.
Yes, AVOSTERIDE is often prescribed alongside alpha-blockers like tamsulosin to enhance urinary symptom relief by relaxing the prostate and bladder neck muscles in addition to reducing prostate size.
Absolutely, AVOSTERIDE is formulated for long-term use with sustained efficacy and safety profiles, making it suitable for chronic management of benign prostatic hyperplasia.
AVOSTERIDE capsules are manufactured under GMP-compliant conditions by Dr Precision, ensuring high quality, consistency, and precision in formulation.
Country Of Origin: India
AVOSTERIDE Capsule is a therapeutic medication that contains Dutasteride, a 5-alpha-reductase inhibitor used primarily for the treatment of benign prostatic hyperplasia (BPH) in men. It works by reducing the size of an enlarged prostate, relieving symptoms such as frequent urination, difficulty starting or stopping urination, and a weak urine stream. AVOSTERIDE also helps in lowering the risk of urinary retention and the need for prostate surgery. Manufactured under stringent quality standards, AVOSTERIDE ensures reliable results and high bioavailability, offering effective long-term management for patients suffering from prostate enlargement.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
AVOSTERIDE Capsule is a specialized medication widely used in the treatment and management of benign prostatic hyperplasia (BPH), commonly known as prostate gland enlargement. The active ingredient in AVOSTERIDE is Dutasteride, a synthetic 5-alpha-reductase inhibitor that works by blocking the conversion of testosterone to dihydrotestosterone (DHT), the primary hormone responsible for prostate enlargement in adult males. Dutasteride effectively reduces serum and intraprostatic DHT levels, which leads to a gradual reduction in prostate size, improved urinary flow, and relief from the urinary symptoms associated with BPH.
Benign prostatic hyperplasia is a common condition affecting aging men, particularly those over the age of 50. It causes the prostate gland to grow in size, which can compress the urethra and restrict normal urine flow. Symptoms of BPH include difficulty initiating urination, weak or interrupted urine stream, frequent urination (especially at night), urgency, incomplete bladder emptying, and sometimes painful urination. These symptoms, though not life-threatening, can significantly affect a man’s quality of life. AVOSTERIDE Capsule is prescribed as a long-term therapy to alleviate these symptoms and reduce the risk of acute urinary retention and the need for invasive surgical procedures.
Dutasteride, the active compound in AVOSTERIDE, inhibits both type I and type II isoforms of the 5-alpha-reductase enzyme. This dual inhibition makes it more effective than Finasteride, which only blocks one type. As a result, Dutasteride achieves a more profound and sustained reduction in DHT levels. Clinical studies have shown that Dutasteride reduces prostate volume by approximately 25% after six months of therapy and improves urinary symptoms within 3 to 6 months of continued use. AVOSTERIDE is often prescribed as monotherapy or in combination with alpha-blockers such as tamsulosin, which further enhance urinary flow and reduce symptom scores.
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
